🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Peripheral T Cell Lymphoma

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas NCT06176690Phase 12 sites📍 Houston📍 Houston Baylor College of Medicine · Tests: C7R.CD30.CAR-EBVST cells Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL NCT06874946Phase 1, Phase 21 site📍 Beijing Peking University People's Hospital · Tests: CD5-targeted CAR-T cells Q702 for the Treatment of Patients With Hematologic Malignancies NCT06712810Phase 12 sites📍 Scottsdale📍 Rochester Mayo Clinic · Tests: Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing NCT06550427n/a1 site📍 Taipei National Taiwan University Hospital · Tests: ctDNA analyzed by phased variant Allo HSCT Using RIC and PTCy for Hematological Diseases NCT05805605Phase 21 site📍 Minneapolis Masonic Cancer Center, University of Minnesota · Tests: Peripheral Blood Stem Cell Transplant, Allopurinol 300 MG, Fludarabine, Cyclophosphamide, Bone Marrow Cell Transplant GVM±R in Patients With Relapsed or Refractory Aggressive NHL. NCT06244368Phase 21 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: GVM±R regimen Sintilimab With P-GEMOX Versus the P-GEMOX in the Teatment of Advanced-stage Extranodal Natural Killer/T Cell Lymphoma NCT06583083Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Sintilimab with P-GEMOX Regimen, P-GEMOX Regimen Golidocitinib and Chidamide for Cutaneous T-Cell Lymphoma NCT07754890Phase 1, Phase 21 site📍 Beijing Peking Union Medical College Hospital · Tests: golidocitinib, Chidamide A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL NCT06966154Phase 1, Phase 21 site📍 Shanghai Fudan University · Tests: tislezumab, golidocitinib, Selinexor Transplantation After Complete Response In Patients With T-cell Lymphoma NCT05444712NA48 sites📍 Amiens📍 Angers📍 Argenteuil Hospices Civils de Lyon · Tests: Chemotherapy + follow up, Chemotherapy + ASCT + follow up Photopheresis in Early-stage Mycosis Fungoides NCT05680558Phase 21 site📍 New York Columbia University · Tests: UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis, THERAKOS® CELLEX photoph… A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide. NCT05967949n/a1 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: chidamide MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies NCT05735717Phase 21 site📍 Minneapolis Masonic Cancer Center, University of Minnesota · Tests: Fludarabine, Busulfan, Melphalan, Rituximab, Levetiracetam Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma NCT07356245Phase 21 site📍 Columbus Jonathan Brammer · Tests: Ruxolitinib, Positron emission tomography-computed tomography, Bone Marrow Biopsy, Biopsy Procedure, Biospecimen Collec… A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL NCT06855823Phase 1, Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Golicitinib combined with Pomadomide A Prospective Clinical Study on Reduced-intensity Radiotherapy for Stage I/II Low-risk Nasal-type NK/T-cell Lymphoma Achieving Complete Remission After Chemotherapy NCT07628738Phase 21 site📍 Shanghai Ruijin Hospital · Tests: reduced-intensity radiotherapy Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma NCT06151106Phase 21 site📍 Xiamen The First Affiliated Hospital of Xiamen University · Tests: Chidamide combined with Duvillisib Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma NCT07730515Phase 1, Phase 21 site📍 Shanghai Evopoint Biosciences Inc. · Tests: XNW5004 combined with CHOP (incremental), XNW5004 combined with CHOEP (incremental), XNW5004 combined with CHOP (extend… Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of New Diagnosed AITL NCT07168317Phase 21 site📍 Xuzhou The Affiliated Hospital of Xuzhou Medical University · Tests: tislelizumab in combination with cyclophosphamide, mitoxantrone liposomes, chidamide, and prednisone Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma NCT04803201Phase 296 sites📍 Little Rock📍 Duarte📍 La Jolla Alliance for Clinical Trials in Oncology · Tests: Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Etoposide CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma NCT04083495Phase 22 sites📍 Chapel Hill📍 Winston-Salem UNC Lineberger Comprehensive Cancer Center · Tests: ATLCAR.CD30 T cells, Bendamustine, Fludarabine, Cyclophosphamide A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides NCT05296304Phase 13 sites📍 Commack📍 New York📍 Rockville Centre Memorial Sloan Kettering Cancer Center · Tests: Bexarotene, Total Skin Electron Beam (TSEB) Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma NCT07300514Phase 31 site📍 Shanghai Fudan University · Tests: PET-CTandct- DNAdetection, golidocitinib, Placebo Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) NCT06810778Phase 1, Phase 21 site📍 Los Angeles Jonsson Comprehensive Cancer Center · Tests: Duvelisib, Venetoclax A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL NCT05931263Phase 31 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: C-BEAM Regimen, BEAM Regimen Evaluate the Safety and Clinical Activity of HH2853 NCT04390737Phase 1, Phase 225 sites📍 Phoenix📍 Jacksonville📍 Rochester Haihe Biopharma Co., Ltd. · Tests: HH2853 Tablets Dolutegravir Versus Dolutegravir in Combination With Tenofovir for the Treatment of HTLV-1 Infection NCT07555431Phase 21 site📍 Salvador Carlos Brites · Tests: Combination of Dolutegravir + Tenofovir DF for treatment of HTLV-1 infection, Dolutegravir (DTG) JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas NCT06716658Phase 22 sites📍 Tianjin📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: JAK1 Inhibitor Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy NCT07414758Phase 31 site📍 Shanghai Shanghai General Hospital, Shanghai Jiao Tong University Sc… · Tests: golidocitinib, Placebo Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL) NCT07047885Phase 11 site📍 Tampa H. Lee Moffitt Cancer Center and Research Institute · Tests: Ropeginterferon alfa-2b
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy